This trial is evaluating whether Brigatinib will improve 9 primary outcomes and 5 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 28 days.
This trial requires 18 total participants across 1 different treatment group
This trial involves a single treatment. Brigatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Chemotherapy is one of the oldest and most effective treatments of the above cancers. The chemotherapy agents used depend on the specifics of the malignancy, but alkylating agents are often an option. Surgical resection is frequently recommended. Radiation therapy is used commonly in curative situations and is used also to boost the efficacy of other treatments, like chemotherapy or surgery. The use of hormone therapy in treatment of all the above cancers is highly debatable." - Anonymous Online Contributor
"About 12,500 individuals are diagnosed with lung cancer a year in the United States. More than 90% of lung cancers are due to tobacco exposure." - Anonymous Online Contributor
"Mutations during lung development can lead to the development of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) later in life. Furthermore, cancer may develop by a gradual, slow accumulation of tiny changes in the DNA sequences associated with cancer development and progression. This accumulation of mutations is possibly due to a large number of 'driver' mutations, which are responsible for triggering cancer formation." - Anonymous Online Contributor
"The most common presentations of lung cancer are coughing up blood. Other possible presentations include: a persistent fast-spreading rash; hoarseness; a persistent cough with blood or sputum; weight loss; a persistent cough with purulent sputum; and a persistent cough with a change in color of the sputum after coughing. The symptoms of lung carcinoma can be found in an orderly and predictable presentation. Therefore, it is important to have high suspicion for lung cancer when patients present with cough or hoarseness." - Anonymous Online Contributor
"A substantial number of patients with lung carcinoma had a favorable outcome under optimal treatment. Survival after lung carcinoma resection was significantly higher than observed in current retrospective studies. This raises the question of whether, in addition to chemotherapy, adjuvant treatment is necessary to improve survival in early-stage lung carcinoma." - Anonymous Online Contributor
"Carcinoma, non-small-Cell Lung is a very aggressive tumor. It is a disease that requires a high degree of diagnosis and treatment. The initial histology is significant in determining what methods of therapy will work best. The current clinical trials that use targeted treatments or agents (e.g. Immuno-oncology) will also determine the best approach. Clinical trials have not progressed to the point where a cure exists for this disease. Patients diagnosed with this type of cancer will need to be closely monitored to determine the best options for this disease. For more patient information about carcinoma, non-small-cell lung send us a note to [power." - Anonymous Online Contributor
"Brigatinib treatment decreases the tumor size of pre-clinical hepatocellular carcinoma models. Moreover, brigatinib treatment is associated with regression of pre-existing advanced pre-clinical lung fibrosis. Findings from a recent study demonstrate that brigatinib may be an effective treatment for patients with HCC and advanced lung fibrosis. http://www.wustl.edu/krauss/courses/courses_archive/CE/F_lectures.zip file\n\n1. Is the person on insulin therapy the same as me?\n\n2. Can I use the insulin pump?\n\n3." - Anonymous Online Contributor
"The majority of patients (80.0%) and caregivers were satisfied with brigatinib in terms of HRQOL, and no clinically significant changes in QOL were identified between the placebo and brigatinib groups." - Anonymous Online Contributor
"The present study has not replicated a previous report of a high prevalence of lung cancer among NSCLC in families. This may be due to several reasons. First, the earlier study may have been underpowered to detect small mutations of the tumor suppressor gene. Second, if this mutation had been detected, it did not affect carrier status. Third, a different mechanism of lung carcinogenesis may exist in this region." - Anonymous Online Contributor
"The age at diagnosis may reflect a delay in treatment if these are diagnosed late stage. It may additionally reflect an effect of smoking which is a risk factor for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer). Future studies should address the question of whether screening, awareness, intervention and treatment with adjuvant treatment are indicated for all patients at diagnosis but especially in middle-aged patients where cancer remains a major cause of death." - Anonymous Online Contributor
"While there are not many published studies on trials for NSCLC in people on systemic chemotherapy, a recent review of 5 randomized trials found that there was significant benefit to some therapies for chemotherapy induced nausea and vomiting, which is often a very serious issue for these patients. These trials also found significant benefit in pain and fatigue. The authors concluded, 'We are encouraged by the significant improvements in clinical outcomes that have been noted on meta.analysis and by the large number of patients enrolled across randomized trials." - Anonymous Online Contributor
"It is clear that the current therapeutic advances in treating non-small-cell lung cancer are still incomplete. In order to better understand the clinical treatment of NSCLC, it is necessary to develop more effective drugs to be selected." - Anonymous Online Contributor